Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Ideaya Biosciences Inc (IDYA)

Upturn stock ratingUpturn stock rating
Ideaya Biosciences Inc
$27.73
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/09/2024: IDYA (3-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 53.86%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 51
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 12/09/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 53.86%
Avg. Invested days: 51
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/09/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.40B USD
Price to earnings Ratio -
1Y Target Price 54.87
Dividends yield (FY) -
Basic EPS (TTM) -2.33
Volume (30-day avg) 954964
Beta 0.86
52 Weeks Range 25.20 - 47.73
Updated Date 12/10/2024
Company Size Mid-Cap Stock
Market Capitalization 2.40B USD
Price to earnings Ratio -
1Y Target Price 54.87
Dividends yield (FY) -
Basic EPS (TTM) -2.33
Volume (30-day avg) 954964
Beta 0.86
52 Weeks Range 25.20 - 47.73
Updated Date 12/10/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -5730.6%

Management Effectiveness

Return on Assets (TTM) -15.85%
Return on Equity (TTM) -21.1%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE 4.65
Enterprise Value 1500706694
Price to Sales(TTM) 611.11
Enterprise Value to Revenue 382.64
Enterprise Value to EBITDA -7.8
Shares Outstanding 86431800
Shares Floating 85536366
Percent Insiders 1.04
Percent Institutions 111.21
Trailing PE -
Forward PE 4.65
Enterprise Value 1500706694
Price to Sales(TTM) 611.11
Enterprise Value to Revenue 382.64
Enterprise Value to EBITDA -7.8
Shares Outstanding 86431800
Shares Floating 85536366
Percent Insiders 1.04
Percent Institutions 111.21

Analyst Ratings

Rating 4.67
Target Price 36.08
Buy 3
Strong Buy 11
Hold 1
Sell -
Strong Sell -
Rating 4.67
Target Price 36.08
Buy 3
Strong Buy 11
Hold 1
Sell -
Strong Sell -

AI Summarization

Ideaya Biosciences Inc. (IDYA): Comprehensive Overview

Company Profile

History and Background: Founded in 2015, Ideaya Biosciences is a clinical-stage biotechnology company focused on developing novel therapies for neurological and neurodevelopmental disorders. The company emerged from Pfizer's venture capital arm and has its headquarters in Morrisville, North Carolina.

Core Business Areas: Ideaya focuses on two main areas:

  • Gene therapy: Leveraging adeno-associated virus (AAV) vectors to deliver therapeutic genes to specific regions of the brain.
  • Small molecule therapies: Developing small molecules that modulate key pathways associated with neurological disorders.

Leadership and Corporate Structure:

  • Yujiro Hata, MD, PhD: President and CEO, with extensive experience in drug development and commercialization.
  • Michael Kishbauch, PhD: Chief Scientific Officer, leading the research and development efforts.
  • Maria Collazo, MBA: Chief Financial Officer, responsible for financial strategy and operations.

Top Products and Market Share

Top Products:

  • IDE163: A gene therapy for treating Fragile X syndrome in development.
  • IDE399: A gene therapy for treating Rett syndrome in development.
  • IDE019: A small molecule therapy for treating epilepsy in development.

Market Share: Ideaya currently has no marketed products. As a clinical-stage company, its market share is limited to its development pipeline. However, its potential target markets are significant:

  • Fragile X syndrome: 400,000-600,000 individuals worldwide.
  • Rett syndrome: 350,000 individuals worldwide.
  • Epilepsy: 50 million individuals worldwide.

Competitive Landscape: Competitors in the gene therapy space for neurological disorders include AveXis, BioMarin, and Orchard Therapeutics. In the small molecule epilepsy space, competitors include UCB, Eisai, and GW Pharmaceuticals.

Total Addressable Market

The total addressable market for Ideaya's potential products is estimated to be over $10 billion globally, with significant growth potential as the understanding and treatment of neurological disorders evolve.

Financial Performance

Recent Financials: As of June 30, 2023, Ideaya reported:

  • Revenue: $0 (pre-commercial stage)
  • Net Income: $(44.2) million
  • Cash and Cash Equivalents: $273.5 million

Financial Health: The company has a solid cash position to fund ongoing clinical trials. However, it is important to note that as a clinical-stage company, Ideaya is not yet profitable and relies on external funding to support its operations.

Dividends and Shareholder Returns

Dividend History: Ideaya does not currently pay dividends.

Shareholder Returns: Since its IPO in 2021, Ideaya's stock price has been volatile, reflecting the uncertainties associated with its clinical-stage pipeline.

Growth Trajectory

Historical Growth: Ideaya has demonstrated rapid growth in its early years, fueled by funding rounds and advancements in its development pipeline.

Future Growth: The company's future growth will depend on the success of its clinical trials and subsequent commercialization efforts. If successful, Ideaya has the potential to become a significant player in the neurology market.

Market Dynamics

Industry Trends: The market for neurological therapies is growing rapidly, driven by increasing prevalence of neurological disorders and advancements in technology.

Competitive Landscape: The market is becoming increasingly competitive, with several companies vying for market share. However, Ideaya's focus on gene therapy and rare neurological disorders provides it with a unique opportunity.

Competitors

Key Competitors:

  • Gene Therapy: AveXis (AVXS), BioMarin (BMRN), Orchard Therapeutics (ORTX)
  • Small Molecule Epilepsy: UCB (UCBJF), Eisai (OTCPK:ESALY), GW Pharmaceuticals (GWPH)

Competitive Advantages: Ideaya's differentiated gene therapy platform and focus on rare neurological disorders could provide it with a competitive advantage.

Competitive Disadvantages: The company's lack of marketed products and late-stage clinical assets compared to its competitors is a disadvantage.

Potential Challenges and Opportunities

Challenges:

  • Clinical Trial Risks: The success of Ideaya's development pipeline is not guaranteed, and clinical trials can be expensive and time-consuming.
  • Competition: The company faces intense competition in both the gene therapy and small molecule epilepsy markets.
  • Regulatory Approval: Obtaining regulatory approval for new therapies can be challenging and lengthy.

Opportunities:

  • Large Market Potential: The market for neurological therapies is vast and growing rapidly.
  • Technological Advancements: New technologies in gene therapy and drug discovery could provide Ideaya with a competitive edge.
  • Strategic Partnerships: Collaborations with other companies could accelerate Ideaya's development and commercialization efforts.

Recent Acquisitions

Ideaya has not made any acquisitions in the last three years.

AI-Based Fundamental Rating

Rating: 7/10

Justification: Ideaya has a promising pipeline of gene therapy and small molecule candidates targeting significant unmet medical needs. The company's strong leadership team and financial backing position it well for future growth. However, clinical trial risks and competition remain key challenges.

Sources:

Disclaimer:

This information is provided for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Ideaya Biosciences Inc

Exchange NASDAQ Headquaters South San Francisco, CA, United States
IPO Launch date 2019-05-23 President, CEO & Director Mr. Yujiro S. Hata
Sector Healthcare Website https://www.ideayabio.com
Industry Biotechnology Full time employees 124
Headquaters South San Francisco, CA, United States
President, CEO & Director Mr. Yujiro S. Hata
Website https://www.ideayabio.com
Website https://www.ideayabio.com
Full time employees 124

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​